AbCellera Biologics Inc.
ABCL · NASDAQ
Financial statements
Annual and quarterly income, balance-sheet, cash-flow and key-statistics data.
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2022 FY | 485.42M | 418.99M | 216.51M | 158.52M | 0.56 |
| 2023 FY | 38.03M | 38.03M | -237.21M | -146.40M | -0.51 |
| 2024 FY | 28.83M | 28.83M | -314.77M | -162.86M | -0.55 |
| 2025 FY | 75.13M | 46.31M | -217.10M | -146.41M | -0.49 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2022 FY | 1.54B | 307.63M | 386.54M | 82.26M | 1.23B |
| 2023 FY | 1.49B | 335.78M | 133.32M | 77.38M | 1.15B |
| 2024 FY | 1.36B | 304.47M | 156.33M | 65.36M | 1.06B |
| 2025 FY | 1.36B | 390.05M | 128.51M | 143.22M | 966.90M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2022 FY | 277.36M | -72.66M | 204.70M | — | -86.49M |
| 2023 FY | -43.88M | -77.51M | -121.38M | — | -254.04M |
| 2024 FY | -108.56M | -78.40M | -186.95M | — | 23.01M |
| 2025 FY | -131.30M | -42.77M | -174.07M | — | -28.37M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2022 FY | 2.89B | 2.58B | — | — | — |
| 2023 FY | 1.65B | 1.60B | — | — | — |
| 2024 FY | 862.38M | 771.42M | — | — | — |
| 2025 FY | 1.02B | 1.04B | — | — | — |
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 Q2 | 17.08M | 17.08M | -49.59M | -34.73M | -0.12 |
| 2025 Q3 | 8.96M | 8.96M | -76.28M | -57.12M | -0.19 |
| 2025 Q4 | 44.85M | 36.93M | -28.58M | -8.95M | -0.03 |
| 2026 Q1 | 8.32M | -340.00K | -57.52M | -43.17M | -0.14 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2025 Q2 | 1.40B | 394.99M | 92.44M | 142.08M | 1.01B |
| 2025 Q3 | 1.36B | 391.95M | 83.16M | 142.22M | 964.04M |
| 2025 Q4 | 1.36B | 390.05M | 128.51M | 143.22M | 966.90M |
| 2026 Q1 | 1.31B | 369.03M | 77.06M | 140.18M | 938.08M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2025 Q2 | -32.40M | -13.37M | -45.77M | — | -66.83M |
| 2025 Q3 | -52.59M | -8.93M | -61.52M | — | -9.28M |
| 2025 Q4 | -34.74M | -9.84M | -44.59M | — | 44.80M |
| 2026 Q1 | -33.52M | -3.83M | -37.35M | — | -52.95M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2025 Q2 | 1.02B | 1.07B | — | — | — |
| 2025 Q3 | 1.50B | 1.56B | — | — | — |
| 2025 Q4 | 1.02B | 1.04B | — | — | — |
| 2026 Q1 | 1.06B | 1.12B | — | — | — |